Related Experiment Videos
Circulating tumor markers in cervical cancer.
P Benedetti Panici1, G Scambia, G Baiocchi
1Department of Gynecology, Catholic University, Rome, Italy.
Summary
Serum CA 125 and CA 15-3 levels show promise for managing cervical cancer. These biomarkers correlate with disease stage and chemotherapy response, aiding clinical decisions.
Area of Science:
- Oncology
- Biochemistry
Background:
- Cervical cancer management relies on accurate staging and monitoring treatment efficacy.
- Tumor markers are valuable tools in oncology for disease assessment.
Purpose of the Study:
- To evaluate the clinical utility of serum tumor markers CA 19-9, CA 125, and CA 15-3 in cervical cancer patients.
- To assess the correlation of these markers with disease stage, differentiation, and response to neoadjuvant chemotherapy.
Main Methods:
- Serum levels of CA 19-9, CA 125, and CA 15-3 were measured in 91 cervical cancer patients.
- Marker levels were monitored monthly during neoadjuvant chemotherapy in 35 locally advanced cases.
Main Results:
- CA 19-9 showed low sensitivity (7.3%) for cervical cancer.
- CA 125 and CA 15-3 were elevated in 31.9% and 23.1% of patients, respectively (combined sensitivity ~40%).
- CA 125 and CA 15-3 levels correlated positively with clinical stage and tumor differentiation, and over 80% of cases showed correlation with chemotherapy response.
Conclusions:
- CA 125 and CA 15-3 are potential biomarkers for cervical cancer management.
- These markers may aid in assessing disease progression and treatment effectiveness.